DUBLIN--(BUSINESS WIRE)--The "Peanut Allergy R&D Pipeline Analysis Report, H2-2018" report has been added to ResearchAndMarkets.com's offering.
The Peanut Allergy pipeline guide presents complete overview of drugs currently being developed for Peanut Allergy. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Peanut Allergy pipeline candidate.
Research and Development progress along with latest news related to each of the Peanut Allergy pipeline candidates is included.
Major companies participating in therapeutic development of Peanut Allergy are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.
Amid strong interest for cure of Peanut Allergy from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Peanut Allergy clinical and pre clinical products.
The report assists in identifying potential upcoming companies and drugs in Peanut Allergy pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Key Topics Covered:
I. Key Findings
1. Companies Investing in Peanut Allergy Pipeline include
2. Pipeline Candidates
II. Insights into Peanut Allergy Pipeline
4. Peanut Allergy Pipeline by Mechanism of Action
III. Peanut Allergy Pipeline Compound Details
2. Drug Overview
IV. Peanut Allergy Pipeline Company Briefs
V. Latest News and Developments in Global Peanut Allergy Pipeline Market
VI. Appendix
